<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 14(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT: November 30, 1999
EXACT NAME OF REGISTRANT: AMARILLO BIOSCIENCES, INC. (the "Company")
STATE OR OTHER JURISDICTION OF INCORPORATION: Texas
COMMISSION FILE NUMBER: 0-20791
IRS EMPLOYER IDENTIFICATION NUMBER: 75-1974352
ADDRESS OF PRINCIPAL EXECUTIVE OFFICES: 800 W. 9th, Amarillo, Texas 79101
REGISTRANT'S TELEPHONE NUMBER: 806/376-1741
ITEM 5:
On September 30, 1999, the Company entered into an Agreement to Convert
Debt ("Agreement") with Hayashibara Biochemical Laboratories, Inc., a Japanese
corporation ("HBL"). On October 15, 1999, pursuant to this Agreement, the
Company issued 1,111,831 shares of its common stock to HBL in exchange for the
release of $1,005,486.30 in debt and accrued interest.
The Agreement called for an exchange to take place on November 30,
1999, in which HBL would contribute $1,000,000 to the Company and receive an
equivalent amount of the Company's common stock. By mutual consent, the Company
and HBL have agreed that the November 30, 1999 transaction called for under the
Agreement will not take place. Instead, HBL has loaned $1,000,000 to the Company
at an interest rate of 4 1/2%, compounded annually.
This mutual consent does not affect the third transaction called for
under the Agreement, to take place on February 29, 2000.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: Dec 21, 1999.
-------
AMARILLO BIOSCIENCES, INC.
By: /s/ EDWARD L. MORRIS
----------------------------------
Edward L. Morris, Secretary
